Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Holistic Sanctuary Rebukes the New Republic’s Attempt to Destigmatize Buprenorphine and Suboxone
  • USA - English


News provided by

The Holistic Sanctuary

Dec 02, 2013, 11:00 ET

Share this article

Share toX

Share this article

Share toX

Oceanfront Paradise
Oceanfront Paradise
Vimeo
Vimeo

Use of suboxone is many things, ranging from physically harmful and emotionally debilitating to lethal, but is not a good drug, never mind a wondrous one.

Post this

Los Angeles, CA (PRWEB) December 02, 2013 -- The Holistic Sanctuary announces its rebuke concerning a recent column (“The Media Needs to Stop Stigmatizing Our Best Weapon Against Heroin Addiction”) in The New Republic, in which the writer urges his fellow journalists to reevaluate or stop their criticism about buprenorphine and suboxone.(1) Alec MacGillis, the author of the article, faults the New York Times for running their own (mild, in the judgment of The Holistic Sanctuary) two-day series about the toxic and lethal dangers associated with suboxone, as well as the overly aggressive marketing tactics of Reckitt Benckiser, makers of the drug.(2)

Mr. MacGillis also writes that buprenorphine “has proven so successful at allowing opiate addicts to feel normal and go about their lives that advocates hail it as something of a wonder drug.”(3) He concludes by attacking alarmist headlines about suboxone and subutex, saying: “It would be deeply unfortunate if fraught portrayals in the media with decidedly oversimplified, alarmist headlines had the side effect of dulling one of the best tools we have in this fight.”(4)

And yet, the column does not reference the straightforward, on-the-record dangers of suboxone, as documented by the Food and Drug Administration (FDA). The agency’s non-alarmist headline, titled “Information for Pharmacists,” states: “Significant respiratory depression has been associated with buprenorphine, particularly when administered intravenously. A number of deaths have occurred when addicts have intravenously misused buprenorphine, usually with benzodiazepines concomitantly. Deaths have also been reported in association with concomitant administration of buprenorphine and other depressants such as alcohol or other opioids.”(5)

These threats go well beyond a single news story or government report, since the Centers for Disease Control and Prevention (CDC) now report that unsupervised ingestion of buprenorphine-containing products by children is listed as a growing concern.(6) Long before this latest threat, the Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment warned about physicians who may lack sufficient knowledge to prescribe buprenorphine appropriately, or do not have the resources or motivation to adequately monitor patients’ progress post-prescription. Patients – driven by various motivations – also contribute to this crisis through evasive and deceptive behaviors such as “doctor-shopping.”(7) Even on a regional level, in a city like Baltimore, the news about buprenorphine does not reconcile with The New Republic’s description of a wonder drug. The Baltimore Sun reveals that a third to a half of the buprenorphine patients in area clinics flunked urine tests, indicating that they had been taking illegal or unauthorized drugs. People treated with suboxone do no better or worse than addicts on any other type of treatment, the article states.(8)

In addition, the Center for Substance Abuse Research (CESAR) at the University of Maryland at College Park, reports that more than half of buprenorphine-related emergency department visits in the U.S. are for nonmedical use of the drug, according to data from the Drug Abuse Warning Network (DAWN). Of the estimated 23,450 emergency department visits in which buprenorphine was involved as either a direct cause or a contributing factor to the visit, 61% were for nonmedical use of the drug.(9) And finally, among teenagers and young adults treated in emergency rooms for any reason, 10.4 percent admit they have misused a prescription painkiller such as buprenorphine at least once in the last year.(10) Again, these factors all run counter to the New Republic’s use of the words wonder drug, given the health threats connected to buprenorphine.

For Johnny Tabaie, “Johnny The Healer,” (see also http://www.johnnythehealer.com/) the Founder of The Holistic Sanctuary, permanently ending addiction and eradicating dependency on suboxone and other drugs is a top priority, courtesy of his exclusive and natural solution known as the Pouyan Method. This treatment targets the origins of addiction, rejuvenating and restoring brain cells to their pre-addictive state.

Most importantly, Johnny does not classify or treat addiction as a lifelong, incurable disease, which requires daily consumption of several prescription medications (which have never been tested as a single unit, in their combined formulation), enrollment in 12-step programs, belittling duties like mopping floors or reliance on other antiquated and ineffective techniques. His inspiring video testimonials from guests are independent proof of his achievements. People can watch these inspiring stories at: theholisticsanctuary.com/Ibogaine-Videos/.

“Buprenorphine or suboxone is no way a wonder drug worthy of praise or increased popularization. It is, in truth, a potentially deadly drug, which is considerably more difficult to treat than dependency on heroin or other opiates. The New Republic does its readers a disservice by minimizing or outright dismissing the magnitude of this epidemic and its implications among people of all ages, including children. Use of suboxone is many things, ranging from physically harmful and emotionally debilitating to lethal, but is not a good drug, never mind a wondrous one,” says Mr. Tabaie.

Prospective patients can also see the undeniable evidence of The Holistic Sanctuary’s success involving the healing of the brain by clicking Pouyan Method Brain Scans (theholisticsanctuary.com/Brain-Scan/).

About The Holistic Sanctuary
The Holistic Sanctuary is the home of the exclusive, all-natural and proprietary Pouyan Method, which enables patients to permanently end a variety of addictions. Unlike conventional drug and alcohol rehabilitation centers, which have rates or failure or relapse among patients, The Holistic Sanctuary offers a customized protocol with the amenities of a 5-star resort. We seek to stop addiction without prescription medication or the use of 12-step programs. Nor do we classify patients as victims of an incurable disease. Our therapies focus on healing the brain, so a patient can heal their life. For more information about our innovative techniques, founding principles and testimonials from former patients, please visit http://www.theholisticsanctuary.com.

1. newrepublic.com/article/115640/buprenorphine-heroin-addiction-pill-stigmatized-media; ("The Media Needs to Stop Stigmatizing Our Best Weapon Against Heroin Addiction"), November 19, 2013.
2. nytimes.com/2013/11/17/health/in-demand-in-clinics-and-on-the-street-bupe-can-be-savior-or-menace.html?hp; ("Addiction Treatment With a Dark Side"), November 16, 2013.
3. newrepublic.com/article/115640/buprenorphine-heroin-addiction-pill-stigmatized-media; ("The Media Needs to Stop Stigmatizing Our Best Weapon Against Heroin Addiction"), November 19, 2013.
4. Ibid.
5. fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM191533.pdf; ("Information for Pharmacists"), December 2012.
6. cdc.gov/mmwr/preview/mmwrhtml/mm6203a5.htm; ("Notes from the Field: Emergency Department Visits and Hospitalizations for Buprenorphine Ingestion by Children — United States, 2010–2011"), January 25, 2013.
7. buprenorphine.samhsa.gov/Buprenorphine_FinalReport_12.6.06.pdf; ("Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators"), November 30, 2006.
8. articles.baltimoresun.com/2007-12-18/news/0712180042_1_drug-addiction-heroin-addicts-buprenorphine; ("Not a cure-all: Despite praise, `bupe' alone isn't enough to break addicts of destructive routines"), December 18, 2007.
9. cesar.umd.edu/cesar/pubs/20121214%20Buprenorphine%20CESAR%20FAX.pdf; ("Buprenorphine Series"), February 4, 2013 to March 31, 2013.
10. futurity.org/1-10-teens-misuse-prescription-painkillers/; ("1 In 10 Teens Admit They Misused Painkillers"), October 31, 2013.
The Holistic Sanctuary
Attn: Media Relations
[email protected]
Los Angeles, California
310-601-7805

Johnny Tabaie, The Holistic Sanctuary, http://www.theholisticsanctuary.com, +1 310-601-7805, [email protected]

Modal title

Private Master Suites
Private Master Suites
World CLass Healing
World CLass Healing
Meet Johnny The Healer
Meet Johnny The Healer
Ocean Front Paradise The Holistic Sanctuary Healing Center
Ocean Front Paradise The Holistic Sanctuary Healing Center
The Holistic Sanctuary Healing Center
The Holistic Sanctuary Healing Center
Private Master Suites World CLass Healing Meet Johnny The Healer Ocean Front Paradise The Holistic Sanctuary Healing Center The Holistic Sanctuary Healing Center

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.